Urinary Neutrophil Gelatinase-associated Lipocalin in the evaluation of Patent Ductus Arteriosus and AKI in Very Preterm Neonates: a cohort study

Table 3 Influence of perinatal characteristics, sepsis, renal parameters, AKI, and PDA on U-NGAL in 146 very preterm neonates

		Percent change in U-NGAL Day 3
	Crude	Adjusted GA, gender	Adjusted GA, gender, sepsis
Per gestational week	−17 (−23; −10)
Girls only	−12 (−22; −0.2)
Boys only	−20 (−27; −12)
Male gender vs. female	−58 (−70; −40)
Sepsis vs. no sepsis	329	240 (103; 466)
Per percent increase SCr	0.4	0.3 (−0.6; 1.2)	0.7 (−0.2; 1.5)
Per percent increase urine albumin	0.6	0.5 (0.3; 0.7)	0.5 (0.3; 0.6)
Per percent increase FENa	0.7	0.5 (0.2; 0.8)	0.3 (0.0; 0.6)
PDA vs. no PDA day 3	53	0.3 (−30; 40)	0.4 (−27; 35)
Small PDA vs. no PDA	70	14 (−27; 76)	0.0 (−32; 47)
Large PDA vs. no PDA	42	−5 (−34; 38)	2.3 (−32; 41)
AKI vs. no AKI	−15	−18 (−63; 80)	−25 (−63; 52)
AKI vs. no AKI	34^a	24 (−60; 295)	19 (−60; 269)

Percent change in U-NGAL (95% CI) concentration by one unit increase in gestational age, by 1% increase in SCr, urinary albumin, and FENa and difference in concentration between groups (male vs. female, sepsis vs. no sepsis, PDA vs. no PDA, AKI vs. no AKI). ^aU-NGAL measured day 6 in 126 neonates all other U-NGAL was measured day 3
U-NGAL urine neutrophil gelatinase-associated lipocalin, GA gestational age, SCr serum creatinine, FENa fractional excretion of sodium, AKI acute kidney injury, PDA diameter < 1.5 mm small PDA, PDA diameter ≥ 1.5 mm large PDA

ISSN: 1471-2431